A Study of MK-6837 as a Monotherapy and Combination Therapy …
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MK-6837, administered as a monotherapy and in combination with pembrolizumab (MK-3475), in participants with histologically or cytologically confirmed advanced/metastatic solid tumors that have not responded to conventional therapy.
MK-6837 by Merck for Solid Tumor: Likelihood of Approval
2025年1月6日 · MK-6837 is under clinical development by Merck and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II.
Michael Kors Ritz Quartz Crystal White Dial Ladies Watch MK6837
Fixed rose gold-tone bezel set with crystals. White dial with rose gold-tone hands and crystal-tipped index hour markers. Minute markers around the outer rim. Dial Type: Analog. Quartz movement. Scratch resistant mineral crystal. Pull / push …
派姆单抗 和 MK-6837 在 肿瘤转移-临床试验注册中心-ICH GCP
2024年6月11日 · 本研究的目的是评估 MK-6837 作为单一疗法以及与派姆单抗 (MK-3475) 联合用药在经组织学或细胞学证实的晚期/晚期参与者中的安全性、耐受性、药代动力学 (PK) 和初步疗效。 对常规治疗没有反应的转移性实体瘤。 研究中不会进行任何假设检验。 本节提供了进行研究的人员的详细联系信息，以及有关进行该研究的地点的信息。 研究人员寻找符合特定描述的人，称为资格标准。 这些标准的一些例子是一个人的一般健康状况或先前的治疗。 在第一剂研究干预 …
Pembrolizumab and MK-6837 in Neoplasm Metastasis - ICH GCP
2024年6月11日 · The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MK-6837, administered as a monotherapy and in combination with pembrolizumab (MK-3475), in participants with histologically or cytologically confirmed advanced/metastatic solid tumors that have not responded to conventional therapy.
MK 6837 - AdisInsight - Springer
2024年8月9日 · Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases. MK 6837 is being developed by Merck for the treatment of solid tumours. Clinical development is underway in the US and Israel.
MK-6837 / Merck (MSD) - LARVOL
Combination therapy • Metastases • Monotherapy • New P1 trial • Oncology • Solid Tumor.
A Phase 1 Open-label, Multicenter Study of MK-6837 as
Adis is an information provider. Final gross price and currency may vary according to local VAT and billing address. Your purchase entitles you to full access to the information contained in …
A Phase 1 Open-label, Multicenter Study of MK-6837 ... - Monash …
2024年8月30日 · A Phase 1 Open-label, Multicenter Study of MK-6837 as Monotherapy and Combination Therapy in Participants with Advanced/Metastatic Solid Tumors
A Study of MK-6837 as a Monotherapy and Combination Therapy …
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of MK-6837, administered as a monotherapy and in combination with pembrolizumab (MK-3475), in participants with histologically or cytologically confirmed advanced/metastatic solid tumors that have not responded to conventional t...